Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous drug delivery
Pharma
After FDA delay, Sanofi scores subcutaneous OBI nod for Sarclisa
Sanofi has gained FDA approval of its subcutaneous version of Sarclisa, which can be delivered manually or by way of an on-body injector.
Kevin Dunleavy
Jul 10, 2026 9:18am
Vertex taps Halozyme in $15M upfront biologics drug delivery deal
Apr 7, 2026 10:17am
On-body injected version of Amgen's Tepezza measures up to IV
Apr 6, 2026 9:43am
Biogen taps Alteogen for help developing 2 subQ biologics
Mar 25, 2026 10:55am
Halozyme catches M&A wave to snap up Surf Bio
Jan 28, 2026 2:06pm
GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
Jan 20, 2026 2:26pm
